Zavesca added to CMS drug demo
Coverage of Actelion/Celltech's oral Gaucher's disease therapy Zavesca (miglustat) has been added to the Medicare Part B drug replacement demonstration project, according to CMS. The demonstration project now provides for interim coverage of approximately 30 oral or self-injected replacements for physician-administered drugs. Enrollment in the project has been described as predictive of enrollment trends in the upcoming Part D benefit (1"The Pink Sheet" July 25, 2005, p. 26)...
You may also be interested in...
Enrollment challenges with the Medicare oral drug replacement demonstration project are highlighting possible stumbling blocks in the Part D implementation process
Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker
Vacci Prep is first “supplement to establish a standard of care for consumers when preparing their immune system for vaccinations,” Dentovations says.